Glucocorticoids, cytokines and brain abnormalities in depression

@article{Zunszain2011GlucocorticoidsCA,
  title={Glucocorticoids, cytokines and brain abnormalities in depression},
  author={Patricia A. Zunszain and Christoph Anacker and Annamaria Cattaneo and Livia A. Carvalho and Carmine Maria Pariante},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2011},
  volume={35},
  pages={722-729}
}

Figures from this paper

Inflammation and depression.

The evidence linking inflammation and MDD is discussed, looking at data from clinical and animal studies, the role of stress, possible mechanisms and the involvement of genetic polymorphisms.

Cytokine secretion and the risk of depression development in patients with connective tissue diseases

This review explores the complex interrelationships in which inflammatory responses alter neuroendocrine and neuropsychological regulation contributing to depressive symptoms in CTD.

Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

The current state of knowledge regarding HPA-axis pathology in Alzheimer’s, PD and HD is summarized, differentiating between prodromal and later stages of disease progression when evidence is available.

Anti-inflammatory treatment for major depressive disorder

Pre-clinical and clinical studies that have provided support for treatment with non-steroidal antiinflammatory drugs in depressed patients with inflammatory comorbidities or an elevated immune profile are discussed, as well as evidences for anti-inflammatory properties of standard antidepressants.

Neuroimmune and neuroendocrine abnormalities in depression: two sides of the same coin

Further work to delineate the relationship between neuroimmune and neuroendocrine systems in depression will be critical for understanding the biological perturbations underpinning depression, and therefore, for discerning treatment targets.

University of Groningen Anti-inflammatory treatment for major depressive disorder

Pre-clinical and clinical studies that have provided support for treatment with non-steroidal antiinflammatory drugs in depressed patients with inflammatory comorbidities or an elevated immune profile are discussed, as well as evidences for anti-inflammatory properties of standard antidepressants.

The HPA axis dysregulation in severe mental illness: Can we shift the blame to gut microbiota?

Depression and inflammation: Pathophysiology and therapeutic implications

Inflammation appears to play a pivotal role in the pathophysiology of depression but only in subset of depressive patients, and may prove to be an effective target to develop several treatment modalities and thus open avenues for development of potential therapeutic strategies in vulnerable at risk depressive patients.
...

References

SHOWING 1-10 OF 118 REFERENCES

Therapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression?

Correcting the imbalance between the mineralocorticoid receptor and the glucocortioid receptor can facilitate recovery processes still present in the diseased brain, provided that the right psychological context is offered to the individual.

Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression

The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression

A hypothesis integrating current concepts of neurotransmission and hypothalamus–pituitary–adrenal (HPA) axis dysregulation with findings on immunological alterations and alterations in brain morphology in MD is presented.

Glucocorticoid receptors in depression.

Amid intriguing data indicating monoamine regulation of GR number and function in a hormone independent fashion along with the well-known effects of glucocorticoids on behavior, further scrutiny of the role of GR in depression and its treatment is warranted.

Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment.

  • Y. PollakR. Yirmiya
  • Psychology, Biology
    The international journal of neuropsychopharmacology
  • 2002
It is suggested that during medical conditions elevated levels of cytokines directly contribute to the induction of depression, and illness-associated depression should not be underestimated, and should be treated with antidepressant drugs, which may act on the specific physiological mechanisms of this disorder.

Glucocorticoids, depression, and mood disorders: structural remodeling in the brain.

  • B. McEwen
  • Psychology, Biology
    Metabolism: clinical and experimental
  • 2005

The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression

Screening for inflammatory and neurodegenerative processes in depression will allow to discover new I&ND biomarkers, both at the level of gene expression and the phenotype, and elucidate the underlying molecular I &ND pathways causing depression; identify new therapeutic targets in the I& ND pathways; develop new anti-I&ND drugs for these targets; and select existingAnti-I &ND drugs or substances that could augment the efficacy of antidepressants.
...